The FDA warned on July 16 that asthma drug Xolair may be linked to increased risk of heart attacks and strokes. Xolair is sold in the U.S. by Novartis and Genentech, a division of Roche.
An ongoing study has revealed signs that Xolair (omalizumab), which is used to treat asthma and allergies, may be directly related to heart attacks and strokes suffered by study participants. The drug may have also caused abnormal heart rhythm and heart failure in patients treated with Xolair, according to the Food and Drug Administration (FDA). For the FDA warning, see http://ow.ly/hB6L.
The law firm of Aylstock, Witkin, Kreis & Overholtz is investigating possible manufacturer and distributor liability in this case. For updates from our lawyers, see the AWKO Law “Defective Drugs” page at http://ow.ly/hB7v.